Most thyroid-stimulating hormone (TSH) assays now have the sensitivity required by thyroid guidelines and allow the reliable identification of patients with both overt and subclinical hyperthyroidism. Clinical guidelines usually quote decision limits for TSH, but often ignore the issue of whether variability in bias between assays should be considered when such decision limits are implemented. Clinicians and laboratories should appreciate that these decision limits arise largely from historical data that used TSH assays with poorly defined bias. It is thus unlikely that laboratories will be able to apply an appropriate method-related bias adjustment to these TSH cut-offs. Clinicians should appreciate that TSH decision limits should thus be regarded as typical target figures rather than an absolute cut-off and thus can be applied with some degree of flexibility. There is currently insufficient evidence to justify a significant lowering of the upper reference limit for TSH, but fine-tuning of current reference ranges is required since there appears to be no association between the ranking of the assay bias in the UK National External Quality Assessment Service scheme and the manufacturers' quoted reference ranges. There is room for further improvement in TSH assays and this can best be achieved if manufacturers, laboratories and clinicians work together to produce TSH assays and reference ranges that show closer agreement between methods. Until this is achieved, future studies that examine the relationship of TSH with symptoms and treatment should ensure that sufficient information is included in the publication to allow the method related bias of the TSH assay to be clearly described.
Introduction
Thyroid-stimulating hormone (TSH) measurements provide the most sensitive and speci¢c means we have of detecting thyroid dysfunction and as such these measurements rightly have a prominent role in the diagnosis and management of thyroid disorders. Guidelines concerning the laboratory performance of thyroid function tests often de¢ne the required sensitivity of a TSH assay and provide advice on deriving a reference range. 1 Clinical guidelines usually quote decision limits for TSH, but often ignore the issue of whether variability in bias between the various commercial assays should be considered when such decision limits are set or implemented.
Assay sensitivity
Guidelines suggest that laboratories should use a TSH assay with a functional sensitivity of o0.02 mU/L. This sensitivity is required to ensure adequate performance at the 0.1mU/L concentration, which is the clinical action limit most commonly quoted in clinical guidelines, including the recently published 'UK guidelines for the rational use of thyroid function tests'. 2 It has also been suggested that third-generation performance (functional sensitivity 0.01mU/L) is required for detecting subclinical hyperthyroidism, monitoring suppression treatment, detecting TSH-secreting pituitary tumours and distinguishing the low TSH of non-thyroidal illness from hyperthyroidism. 1 There may thus be clinical utility in measuring reliably TSH concentrations between 0.01 and 0.1mU/L.
A functional sensitivity of o0.02 mU/L is now achievable by most of the automated immunoassay platforms. 3 For the past 20 years or so the UK National External Quality Assessment Service (NEQAS) has monitored low-end TSH performance by repeatedly distributing serum samples with TSH concentrations of r 2007 The Association for Clinical Biochemistry o0.1mU/L. The data from these distributions indicate that now o2% of laboratories in the scheme (approximately 400 participants) would report a TSH40.1mU/ L in these low TSH serum samples ( Figure 1 ). The 2% of laboratories that have unacceptable performance comprise non-UK laboratories that use minor methods that fail to meet third-generation performance. Most TSH assays now have the sensitivity required by clinical thyroid guidelines, thus allowing the reliable identi¢cation of patients with both overt and subclinical hyperthyroidism. To our knowledge no External Quality Assessment (EQA) scheme has addressed the issue of assay performance (bias and sensitivity) in routine laboratories at TSH concentrations between 0.01 and 0.1mU/ L. Clearly, such data are required before clinical guidelines begin to recommend treatment/diagnostic regimens using TSH cut-o¡s in this low concentration range.
Assay bias

Thyroid-stimulating hormone reference ranges and bias
Clinicians assume that the laboratory has set an appropriate reference range and will use this to provide an assessment of whether a test result is 'di¡erent' from results found in the healthy population. There has been considerable debate over the suitability of the reference population selected for deriving the TSH reference range. It has been argued that the log-normal distribution of TSH observed in the reference population arises through the inadvertent inclusion of subjects who have mild (subclinical) hypothyroidism. If such subjects could be identi¢ed and excluded, through the use of very sensitive anti-thyroid peroxidase (TPO) measurements and ultrasound screening, it has been suggested that the TSH values would show a Gaussian distribution with a reference range of approximately 0.4--2.5 mU/L. 4, 5 Indeed, in the Study of Health in Pomerania (SHIP-1), a TSH reference range of 0.25--2.12 was found when all subjects with abnormal ultrasound were excluded from the reference population. 6 This study used a TSH assay (LIA-Mat, BYK Sangtec Diagnostica) that is not used in the UK and we are unable to determine how the bias of this assay compares with current mainstream automated analytical systems.We cannot exclude the possibility that the low upper reference limit for TSH found in SHIP-1 may thus in part be due to a negative assay bias. Furthermore, the population included in the SHIP-1 study was taken from an area of Germany that had previously been iodine de¢cient and it has been suggested that this may be a confounding factor. 7 Two further studies using ultrasound screening of the reference population have failed to provide evidence to support a lower upper reference limit with reference ranges of 0.4--3.77 mU/L 8 (German population; Roche Elecsys TSH assay) and 0.4--3.6 mU/L 9 (Danish population Brahms LUMItest; TSH assay) being reported.
Large population surveys using rigorous criteria for selecting a 'healthy' reference population (but excluding ultrasound) have also failed to provide convincing evidence for narrowing the reference range for TSH. For example the National Health and Nutrition Examination Survey (NHANES) study in the USA used a cohort of 14,333 reference subjects who were very carefully selected to exclude those with known thyroid disease and positive anti-TPO antibodies. In this reference population a log normal distribution for TSH was still found with a reference range of 0.45--4.12 mU/L. 10 The NHANES study used a TSH assay from Nichols Institute Diagnostics which is now no longer available and its bias compared with current TSH assays is unclear. A similar reference range of 0.58--4.07 mU/L was found in Denmark using a reference population selected according to the rigorous selection criteria suggested in the National Academy of Clinical Biochemistry (NACB) guidelines for thyroid function testing with TSH being measured byAutodel¢a; Perkin Elmer. 11 A group of leading European endocrinologists recently concluded that there is insu⁄cient evidence to justify lowering the upper reference limit for TSH to 2.5 mU/L; furthermore these endocrinologists argued that to do so may cause more harm than good by increasing the likelihood of over-replacement with thyroxine. 7 A similar view has been voiced by the 'UK guidelines for the rational use of thyroid function tests' 2 and some in the USA. 4 Data from UK NEQAS suggest that reference intervals quoted by diagnostic companies may require some ¢ne-tuning, however. A recent UK NEQAS survey found no association between the ranking of the assay bias in the scheme and the manufacturers quoted reference ranges (Table1). 12 This discrepancy may in part be due to the selection of inappropriate subjects for the reference population and/or perhaps a subtle change in assay bias once the reference range had been set. Whatever the reason, it is an issue that should be addressed by the diagnostic companies, since many laboratories often resort to using the ranges quoted by these companies. Similarly, diagnostic companies should provide trimester-related reference ranges for TSH in pregnancy given the importance to the fetus of a maternal euthyroid state 13, 14 Thyroid-stimulating hormone decision limits and bias Guidelines often advise on 'decision limits' for TSH. These are set primarily with the aim of simplifying, standardizing and optimizing clinical decisions. When these decision limits are set, it is crucial that there is a strong evidence base to support their use. All too often, however, the precision and bias of the assays used in the reference papers that contribute to the evidence base are either unknown or not relevant to current assay methodologies.
Subclinical hyperthyroidism
Some suggest the use of TSH as an aid to guiding the treatment of endogenous subclinical hyperthyroidism. In contrast, the group suggested that:
individuals with a TSH o0.1mU/L con¢rmed by repeat should be considered for treatment if Graves' disease or multinodular goitre was diagnosed. 3, 15, 16 Unfortunately the commonly used automated TSH assays show poor agreement at this low level of TSH concentration, 3 a ¢nding con¢rmed by UK NEQAS ( Table 2 ). Clinicians should be aware of this analytical uncertainty when using TSH to guide treatment of subclinical hyperthyroidism. Thyroid-stimulating hormone as a predictor for the development of overt hypothyroidism
The Whickham Survey and the follow-up study have provided invaluable information on the natural history of thyroid disorders. 17--19 The survey showed that the risk of developing hypothyroidism was related to the original TSH concentration. This relationship only held down to a TSH concentration of 2 mU/L, an observation that was used by some to support the view that the upper reference limit should be lowered. However, we would agree with the view of O'Reilly 20 who pointed out that the assay used for the Whickham Study was a ¢rst-generation radioimmunoassay that was unlikely to be able to measure TSH reliably at concentrations below 2 mU/L. He suggests that this poor sensitivity explains why a link between original TSH concentration and progression to hypothyroidism could not be found in the Whickham Survey at TSH concentrations o2mU/L. 20 Furthermore, since the assay that was used for Whickham is no longer available it is impossible to know how the bias of the radioimmunoassay would compare with current automated systems.
Guiding treatment of subclinical hypothyroidism
It is often suggested that thyroid hormone (T 4 ) replacement is commenced in subclinical hypothyroidism when TSH concentration is persistently 410 mU/L, while patients with a TSH that is elevated but o10 mU/L will derive no bene¢t from treatment and should be monitored. 2, 4, 7, 16, 21, 22 This cut-o¡ arises from a number of large epidemiological studies including the Whickham Survey, the Rotterdam Study 23 and the Colorado Study 24 but the bias of the TSH assays used in these and other studies is often not considered. It is not known how the bias of the TSH radioimmunoassay used for the Whickham Study would compare with today's immunometric assays. The radioimmunoassay used for Whickham would have been calibrated to the ¢rst International Reference Preparation (IRP) for the assay of TSH, while today's immunometric assays are calibrated to the second IRP. The proportion of the various TSH isoforms that comprise the ¢rst and second IRP appear to be quite di¡erent. 25 The data generated by the Colorado Study used a TSH assay produced by Nichols Institute Diagnostics, an assay that was little used in some countries and now no longer available. Similarly, the Rotterdam Study used TSH data generated by the Brahms Lumitest assay, a largely manual method not suited to large diagnostic laboratories. How the bias of the TSH assays used in these and other reference studies compares with the current automated immunoassay systems is often unclear, it is thus di⁄cult (and perhaps in many cases impossible) for laboratories to determine if the 10 mU/L decision limit for TSH should be adjusted to take into account bias of the local assay. Table 3 shows data from UK NEQAS that highlights the marked bias di¡erences between some of the current TSH methodologies at a concentration of endogenous TSH that lies near the decision limit of 10 mU/L. It is clear from these data that the decision to treat patients with subclinical hypothyroidism may be in£uenced to some extent by the bias of the assay. Thus, when faced with managing a patient with subclinical hypothyroidism, the clinician should be aware that the 10 mU/L cut-o¡, mentioned in many guidelines, is subject to some degree of uncertainty. This uncertainty provides the clinician with some £exibility in deciding if treatment with T 4 is appropriate for an individual patient. 2 Table 2 Between-method bias on the UK NEQAS scheme using a pool containing a mean endogenous TSH concentration of 0.13 mU/L Thyroid-stimulating hormone assays and isoforms TSH circulates in multiple isoforms that may be di¡erent to the forms found in the pituitary-derived IRP. Assay bias may to some extent be a consequence of the ability of the antibodies used in TSH assays to detect these various isoforms. The TSH-30 assay (Ortho Clinical Diagnostics) illustrates an extreme example of this. The UK NEQAS scheme distributes samples containing only endogenous TSH and in addition samples are distributed to which has been added the second IRP for TSH. For samples containing the second IRP, the TSH-30 assay produces results that agree well with other assay systems. However, in serum samples that contain only endogenous TSH, the TSH-30 assay shows a large negative bias of some À30% to À40%. 12, 26 Because of this extreme assay bias, epidemiological data generated with the TSH-30 are likely to be highly misleading unless the bias issues relating to this assay are highlighted in the publication. A recent study that examined the role of TSH as predictor of future thyroid dysfunction in patients with diabetes highlights this point. 27 The study found using TSH-30, that a threshold of 1.5 mU/L was a useful discriminator in determining which diabetic patients were subsequently likely to develop a thyroid disorder. The authors pointed out that the absolute value of this cut-o¡ was assay-speci¢c but corresponded to the 75th centile of the reference population. They suggested that it would be more appropriate for centres to de¢ne a cut-o¡ that equated to the 75th centile of the reference population rather than simply use a 1.5 mU/L cut-o¡.
The way forward?
Manufacturers Should strive to produce assays that show closer agreement between methods than is currently the case. This is particularly important at concentrations that may in£uence treatment (i.e. at 0.1 and 10 mU/L ) and perhaps should extend to concentrations as low as 0.01mU/L if measurement of such low doses is con¢rmed to have clinical utility. Careful consideration should be given to the choice of antibody and perhaps to the use of a TSH reference preparation that more closely resembles the TSH isoforms circulating in serum. 28 It would be helpful if manufacturers could work together to achieve this. The recent growth hormone initiative has shown that such collaboration is possible. 29 Should ensure that their published reference ranges are derived from a large population of subjects that have been carefully selected to exclude individuals with evidence of even the most mild thyroid disorders. If the consensus becomes that ultrasound screening in addition to anti-TPO antibody measurements is required to select the reference population this will require considerable collaboration with laboratories and clinicians. Once the ranges have been set it is essential that the assay is not allowed to alter signi¢cantly in terms of bias.
Laboratories
Should appreciate that the cut-o¡s quoted in guidelines often arise from historical data using assays with poorly de¢ned bias that may no longer be available for routine use. In most cases, it is thus unlikely that laboratories will be able to achieve an accurate adjustment of the TSH cut-o¡s quoted in guidelines to take into account bias of the local assay. The cut-o¡s should not be adjusted to compensate for current method bias on an EQA scheme, since this would only be valid if the TSH assays used in the evidence base were known to be accurate.
Clinicians
Guidelines are a very useful tool to optimize and standardize diagnosis and treatment. Clinicians should appreciate, however, that in relation to subclinical thyroid disease the TSH cut-o¡s quoted in guidelines are subject to some uncertainty. These TSH values should therefore be regarded as typical target ¢gures rather than an absolute cut-o¡ and thus can be applied with some degree of £exibility.
Researchers
Future studies that examine the relationship of thyroid function tests with symptoms and treatment should ensure that su⁄cient information is included in the publication to allow the method related bias to be clearly described. This may for example be achieved for TSH by quoting how the particular method used in the publication behaves compared with the All Laboratory Trimmed Mean (ALTM) found in an EQA scheme. The ALTM has been shown to be a very stable entity over many years in the UK NEQAS scheme.
We concluded that on the whole current TSH assays are ¢t for purpose since they identify with a high degree of sensitivity patients with overt thyroid disease Ann Clin Biochem 2007; 44: 203-208 who require treatment. In addition such assays also identify patients with the most minor degrees of thyroid dysfunction where the bene¢ts of treatment are still being debated.When addressing the issue of subclinical thyroid disease, guidelines should take account of the current limitations of these assays particularly with regard to assay bias variability. There is room for further improvement in these assays and this can best be achieved if manufacturers, laboratories and clinicians work closely together.
